Endothelial trans-differentiation in glioblastoma recurring after radiotherapy

Ivana De Pascalis, Liliana Morgante, Simone Pacioni, Quintino Giorgio D’Alessandris, Stefano Giannetti, Lucia Ricci-Vitiani, Maurizio Martini, Matteo Malinverno, Elisabetta Dejana, Luigi M. Larocca, Roberto Pallini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We hypothesized that in glioblastoma recurring after radiotherapy, a condition whereby the brain endothelium undergoes radiation-induced senescence, tumor cells with endothelial phenotype may be relevant for tumor neovascularization. Matched glioblastoma samples obtained at primary surgery and at surgery for tumor recurrence after radiotherapy, all expressing epidermal growth factor receptor variant III (EGFRvIII), were assessed by a technique that combines fluorescent in situ hybridization (FISH) for the EGFR/CEP7 chromosomal probe with immunostaining for endothelial cells (CD31) and activated pericytes (α Smooth Muscle Actin). Five EGFRvIII-expressing paired primary/recurrent glioblastoma samples, in which the tumor cells showed EGFR/CEP7 amplification, were then assessed by CD31 and α Smooth Muscle Actin immunofluorescence. In glomeruloid bodies, the ratio between CD31+ cells with amplified EGFR/CEP7 signal and the total CD31+ cells was 0.23 ± 0.09 (mean ± sem) and 0.63 ± 0.07 in primary tumors and in recurrent ones, respectively (p < 0.002, Student-t test). In capillaries, the ratio of CD31+ cells with amplified EGFR/CEP7 over the total CD31+ cells lining the capillary lumen was 0.21 ± 0.06 (mean ± sem) and 0.42 ± 0.07 at primary surgery and at recurrence, respectively (p < 0.005, Student-t test). Expression of α Smooth Muscle Actin by cells with EGFR/CEP7 amplification was not observed. Then, in glioblastoma recurring after radiotherapy, where the brain endothelium suffers from radiation-induced cell senescence, tumor-derived endothelium plays a role in neo-vascularization.

Original languageEnglish
Pages (from-to)1361-1366
Number of pages6
JournalModern Pathology
Volume31
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Glioblastoma
Radiotherapy
Endothelium
Actins
Neoplasms
Cell Aging
Epidermal Growth Factor Receptor
Smooth Muscle
Endothelial Cells
Radiation
Students
Recurrence
Pericytes
DNA Probes
Brain
Fluorescence In Situ Hybridization
Smooth Muscle Myocytes
Fluorescent Antibody Technique
Phenotype

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

De Pascalis, I., Morgante, L., Pacioni, S., D’Alessandris, Q. G., Giannetti, S., Ricci-Vitiani, L., ... Pallini, R. (2018). Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. Modern Pathology, 31(9), 1361-1366. https://doi.org/10.1038/s41379-018-0046-2

Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. / De Pascalis, Ivana; Morgante, Liliana; Pacioni, Simone; D’Alessandris, Quintino Giorgio; Giannetti, Stefano; Ricci-Vitiani, Lucia; Martini, Maurizio; Malinverno, Matteo; Dejana, Elisabetta; Larocca, Luigi M.; Pallini, Roberto.

In: Modern Pathology, Vol. 31, No. 9, 01.09.2018, p. 1361-1366.

Research output: Contribution to journalArticle

De Pascalis, I, Morgante, L, Pacioni, S, D’Alessandris, QG, Giannetti, S, Ricci-Vitiani, L, Martini, M, Malinverno, M, Dejana, E, Larocca, LM & Pallini, R 2018, 'Endothelial trans-differentiation in glioblastoma recurring after radiotherapy', Modern Pathology, vol. 31, no. 9, pp. 1361-1366. https://doi.org/10.1038/s41379-018-0046-2
De Pascalis I, Morgante L, Pacioni S, D’Alessandris QG, Giannetti S, Ricci-Vitiani L et al. Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. Modern Pathology. 2018 Sep 1;31(9):1361-1366. https://doi.org/10.1038/s41379-018-0046-2
De Pascalis, Ivana ; Morgante, Liliana ; Pacioni, Simone ; D’Alessandris, Quintino Giorgio ; Giannetti, Stefano ; Ricci-Vitiani, Lucia ; Martini, Maurizio ; Malinverno, Matteo ; Dejana, Elisabetta ; Larocca, Luigi M. ; Pallini, Roberto. / Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. In: Modern Pathology. 2018 ; Vol. 31, No. 9. pp. 1361-1366.
@article{44039822de4c4a40a1cfd76ccf6bee06,
title = "Endothelial trans-differentiation in glioblastoma recurring after radiotherapy",
abstract = "We hypothesized that in glioblastoma recurring after radiotherapy, a condition whereby the brain endothelium undergoes radiation-induced senescence, tumor cells with endothelial phenotype may be relevant for tumor neovascularization. Matched glioblastoma samples obtained at primary surgery and at surgery for tumor recurrence after radiotherapy, all expressing epidermal growth factor receptor variant III (EGFRvIII), were assessed by a technique that combines fluorescent in situ hybridization (FISH) for the EGFR/CEP7 chromosomal probe with immunostaining for endothelial cells (CD31) and activated pericytes (α Smooth Muscle Actin). Five EGFRvIII-expressing paired primary/recurrent glioblastoma samples, in which the tumor cells showed EGFR/CEP7 amplification, were then assessed by CD31 and α Smooth Muscle Actin immunofluorescence. In glomeruloid bodies, the ratio between CD31+ cells with amplified EGFR/CEP7 signal and the total CD31+ cells was 0.23 ± 0.09 (mean ± sem) and 0.63 ± 0.07 in primary tumors and in recurrent ones, respectively (p < 0.002, Student-t test). In capillaries, the ratio of CD31+ cells with amplified EGFR/CEP7 over the total CD31+ cells lining the capillary lumen was 0.21 ± 0.06 (mean ± sem) and 0.42 ± 0.07 at primary surgery and at recurrence, respectively (p < 0.005, Student-t test). Expression of α Smooth Muscle Actin by cells with EGFR/CEP7 amplification was not observed. Then, in glioblastoma recurring after radiotherapy, where the brain endothelium suffers from radiation-induced cell senescence, tumor-derived endothelium plays a role in neo-vascularization.",
author = "{De Pascalis}, Ivana and Liliana Morgante and Simone Pacioni and D’Alessandris, {Quintino Giorgio} and Stefano Giannetti and Lucia Ricci-Vitiani and Maurizio Martini and Matteo Malinverno and Elisabetta Dejana and Larocca, {Luigi M.} and Roberto Pallini",
year = "2018",
month = "9",
day = "1",
doi = "10.1038/s41379-018-0046-2",
language = "English",
volume = "31",
pages = "1361--1366",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Endothelial trans-differentiation in glioblastoma recurring after radiotherapy

AU - De Pascalis, Ivana

AU - Morgante, Liliana

AU - Pacioni, Simone

AU - D’Alessandris, Quintino Giorgio

AU - Giannetti, Stefano

AU - Ricci-Vitiani, Lucia

AU - Martini, Maurizio

AU - Malinverno, Matteo

AU - Dejana, Elisabetta

AU - Larocca, Luigi M.

AU - Pallini, Roberto

PY - 2018/9/1

Y1 - 2018/9/1

N2 - We hypothesized that in glioblastoma recurring after radiotherapy, a condition whereby the brain endothelium undergoes radiation-induced senescence, tumor cells with endothelial phenotype may be relevant for tumor neovascularization. Matched glioblastoma samples obtained at primary surgery and at surgery for tumor recurrence after radiotherapy, all expressing epidermal growth factor receptor variant III (EGFRvIII), were assessed by a technique that combines fluorescent in situ hybridization (FISH) for the EGFR/CEP7 chromosomal probe with immunostaining for endothelial cells (CD31) and activated pericytes (α Smooth Muscle Actin). Five EGFRvIII-expressing paired primary/recurrent glioblastoma samples, in which the tumor cells showed EGFR/CEP7 amplification, were then assessed by CD31 and α Smooth Muscle Actin immunofluorescence. In glomeruloid bodies, the ratio between CD31+ cells with amplified EGFR/CEP7 signal and the total CD31+ cells was 0.23 ± 0.09 (mean ± sem) and 0.63 ± 0.07 in primary tumors and in recurrent ones, respectively (p < 0.002, Student-t test). In capillaries, the ratio of CD31+ cells with amplified EGFR/CEP7 over the total CD31+ cells lining the capillary lumen was 0.21 ± 0.06 (mean ± sem) and 0.42 ± 0.07 at primary surgery and at recurrence, respectively (p < 0.005, Student-t test). Expression of α Smooth Muscle Actin by cells with EGFR/CEP7 amplification was not observed. Then, in glioblastoma recurring after radiotherapy, where the brain endothelium suffers from radiation-induced cell senescence, tumor-derived endothelium plays a role in neo-vascularization.

AB - We hypothesized that in glioblastoma recurring after radiotherapy, a condition whereby the brain endothelium undergoes radiation-induced senescence, tumor cells with endothelial phenotype may be relevant for tumor neovascularization. Matched glioblastoma samples obtained at primary surgery and at surgery for tumor recurrence after radiotherapy, all expressing epidermal growth factor receptor variant III (EGFRvIII), were assessed by a technique that combines fluorescent in situ hybridization (FISH) for the EGFR/CEP7 chromosomal probe with immunostaining for endothelial cells (CD31) and activated pericytes (α Smooth Muscle Actin). Five EGFRvIII-expressing paired primary/recurrent glioblastoma samples, in which the tumor cells showed EGFR/CEP7 amplification, were then assessed by CD31 and α Smooth Muscle Actin immunofluorescence. In glomeruloid bodies, the ratio between CD31+ cells with amplified EGFR/CEP7 signal and the total CD31+ cells was 0.23 ± 0.09 (mean ± sem) and 0.63 ± 0.07 in primary tumors and in recurrent ones, respectively (p < 0.002, Student-t test). In capillaries, the ratio of CD31+ cells with amplified EGFR/CEP7 over the total CD31+ cells lining the capillary lumen was 0.21 ± 0.06 (mean ± sem) and 0.42 ± 0.07 at primary surgery and at recurrence, respectively (p < 0.005, Student-t test). Expression of α Smooth Muscle Actin by cells with EGFR/CEP7 amplification was not observed. Then, in glioblastoma recurring after radiotherapy, where the brain endothelium suffers from radiation-induced cell senescence, tumor-derived endothelium plays a role in neo-vascularization.

UR - http://www.scopus.com/inward/record.url?scp=85046101688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046101688&partnerID=8YFLogxK

U2 - 10.1038/s41379-018-0046-2

DO - 10.1038/s41379-018-0046-2

M3 - Article

C2 - 29713042

AN - SCOPUS:85046101688

VL - 31

SP - 1361

EP - 1366

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 9

ER -